Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors

Publisher： Karger

E-ISSN： 1423-0194|87|4|223-232

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.87, Iss.4, 2008-01, pp. : 223-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors?

By  

Neuroendocrinology, Vol. 101, Iss. 1, 2015-01 ,pp. : 45-57

Karger

Access to resources Recommend Favorite

Expression of Somatostatin and Dopamine 2 Receptors in Neuroendocrine Tumours and the Potential Role for New Biotherapies

By  

Neuroendocrinology, Vol. 89, Iss. 3, 2009-03 ,pp. : 308-314

Karger

Access to resources Recommend Favorite

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

By  

Neuroendocrinology, Vol. 102, Iss. 1-2, 2015-03 ,pp. : 18-25

Karger

Access to resources Recommend Favorite

Expression and Function of Somatostatin Receptor Subtype 1 in Human Growth Hormone Secreting Pituitary Tumors Deriving from Patients Partially Responsive or Resistant to Long-Term Treatment with Somatostatin Analogs

By  

Neuroendocrinology, Vol. 79, Iss. 3, 2004-05 ,pp. : 142-148

Karger

Access to resources Recommend Favorite

Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 97, Iss. 4, 2013-05 ,pp. : 347-354

Karger

Access to resources Recommend Favorite